FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2946743921> ?p ?o ?g. }

• W2946743921 endingPage "123" @default.
• W2946743921 startingPage "116" @default.
• W2946743921 abstract "Abstract Objective This study aimed to retrospectively assess the efficacy and safety of anagrelide in cytoreduction therapy‐naïve essential thrombocythemia (ET) patients in a real‐world setting. Method Data from 53 ET patients who received anagrelide as a first‐line therapy were reviewed for patient characteristics, antiplatelet status, cytoreduction status, therapeutic effects, adverse events, thrombohemorrhagic event development, progression to myelofibrosis or acute leukemia, and cause of death. Results The rate of achieving a platelet count of <600 × 10 9 /L during anagrelide monotherapy was 83.0%. Adverse events occurred in 32 of 53 patients, and tended to be slightly more severe in patients with cardiac failure; however, they were mostly tolerable. The therapeutic effect of anagrelide was consistent, regardless of genetic mutation profiles. The incidence of anemia as an adverse event was significantly higher in the CALR mutation‐positive group. Favorable platelet counts were also achieved in patients for whom hydroxyurea was introduced as a replacement for anagrelide or in addition to anagrelide because of unresponsiveness or intolerance to treatment. Conclusion In Japanese cytoreduction therapy‐naïve ET patients, anagrelide administration as a first‐line therapy demonstrated favorable effects in reducing platelet counts, and its safety profile that was generally consistent with those in previous reports." @default.
• W2946743921 created "2019-05-29" @default.
• W2946743921 creator A5002284882 @default.
• W2946743921 creator A5004962063 @default.
• W2946743921 creator A5005421240 @default.
• W2946743921 creator A5014520132 @default.
• W2946743921 creator A5021841583 @default.
• W2946743921 creator A5022668691 @default.
• W2946743921 creator A5032058198 @default.
• W2946743921 creator A5033178635 @default.
• W2946743921 creator A5035232696 @default.
• W2946743921 creator A5036125853 @default.
• W2946743921 creator A5036648871 @default.
• W2946743921 creator A5048891278 @default.
• W2946743921 creator A5066359544 @default.
• W2946743921 creator A5067399580 @default.
• W2946743921 creator A5070269224 @default.
• W2946743921 creator A5082606604 @default.
• W2946743921 creator A5083615429 @default.
• W2946743921 date "2019-06-17" @default.
• W2946743921 modified "2023-10-06" @default.
• W2946743921 title "Efficacy and safety of anagrelide as a first‐line drug in cytoreductive treatment‐naïve essential thrombocythemia patients in a real‐world setting" @default.
• W2946743921 cites W1969315976 @default.
• W2946743921 cites W2006467096 @default.
• W2946743921 cites W2008435254 @default.
• W2946743921 cites W2013609774 @default.
• W2946743921 cites W2020211442 @default.
• W2946743921 cites W2038854221 @default.
• W2946743921 cites W2051259791 @default.
• W2946743921 cites W2067829130 @default.
• W2946743921 cites W2069651950 @default.
• W2946743921 cites W2084838974 @default.
• W2946743921 cites W2085253297 @default.
• W2946743921 cites W2107398329 @default.
• W2946743921 cites W2111497277 @default.
• W2946743921 cites W2121960517 @default.
• W2946743921 cites W2123643903 @default.
• W2946743921 cites W2124975276 @default.
• W2946743921 cites W2133517610 @default.
• W2946743921 cites W2133633030 @default.
• W2946743921 cites W2158207875 @default.
• W2946743921 cites W2158621837 @default.
• W2946743921 cites W2177135392 @default.
• W2946743921 cites W2339658711 @default.
• W2946743921 cites W2416924654 @default.
• W2946743921 cites W2760125330 @default.
• W2946743921 cites W2764282137 @default.
• W2946743921 cites W2765738369 @default.
• W2946743921 cites W2790003237 @default.
• W2946743921 cites W2790700955 @default.
• W2946743921 cites W2794514341 @default.
• W2946743921 cites W2810842433 @default.
• W2946743921 cites W2895193438 @default.
• W2946743921 cites W2896370995 @default.
• W2946743921 cites W2896897287 @default.
• W2946743921 doi "https://doi.org/10.1111/ejh.13265" @default.
• W2946743921 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6851998" @default.
• W2946743921 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31107982" @default.
• W2946743921 hasPublicationYear "2019" @default.
• W2946743921 type Work @default.
• W2946743921 sameAs 2946743921 @default.
• W2946743921 citedByCount "11" @default.
• W2946743921 countsByYear W29467439212019 @default.
• W2946743921 countsByYear W29467439212020 @default.
• W2946743921 countsByYear W29467439212021 @default.
• W2946743921 countsByYear W29467439212022 @default.
• W2946743921 countsByYear W29467439212023 @default.
• W2946743921 crossrefType "journal-article" @default.
• W2946743921 hasAuthorship W2946743921A5002284882 @default.
• W2946743921 hasAuthorship W2946743921A5004962063 @default.
• W2946743921 hasAuthorship W2946743921A5005421240 @default.
• W2946743921 hasAuthorship W2946743921A5014520132 @default.
• W2946743921 hasAuthorship W2946743921A5021841583 @default.
• W2946743921 hasAuthorship W2946743921A5022668691 @default.
• W2946743921 hasAuthorship W2946743921A5032058198 @default.
• W2946743921 hasAuthorship W2946743921A5033178635 @default.
• W2946743921 hasAuthorship W2946743921A5035232696 @default.
• W2946743921 hasAuthorship W2946743921A5036125853 @default.
• W2946743921 hasAuthorship W2946743921A5036648871 @default.
• W2946743921 hasAuthorship W2946743921A5048891278 @default.
• W2946743921 hasAuthorship W2946743921A5066359544 @default.
• W2946743921 hasAuthorship W2946743921A5067399580 @default.
• W2946743921 hasAuthorship W2946743921A5070269224 @default.
• W2946743921 hasAuthorship W2946743921A5082606604 @default.
• W2946743921 hasAuthorship W2946743921A5083615429 @default.
• W2946743921 hasBestOaLocation W29467439211 @default.
• W2946743921 hasConcept C126322002 @default.
• W2946743921 hasConcept C141071460 @default.
• W2946743921 hasConcept C197934379 @default.
• W2946743921 hasConcept C2776738589 @default.
• W2946743921 hasConcept C2779867487 @default.
• W2946743921 hasConcept C2780829020 @default.
• W2946743921 hasConcept C2781057849 @default.
• W2946743921 hasConcept C71924100 @default.
• W2946743921 hasConcept C89560881 @default.
• W2946743921 hasConceptScore W2946743921C126322002 @default.
• W2946743921 hasConceptScore W2946743921C141071460 @default.
• W2946743921 hasConceptScore W2946743921C197934379 @default.

• next